Nuvation Bio Inc. (NUVB)

NYSE: NUVB · Real-Time Price · USD

1.725

-0.095 (-5.22%)

Mar 31, 2025, 1:29 PM EDT - Market open

Nuvation Bio Employees

Nuvation Bio had 220 employees as of December 31, 2024. The number of employees increased by 169 or 331.37% compared to the previous year.

Employees

220

Change (1Y)

169

Growth (1Y)

331.37%

Revenue / Employee

$35,786

Profits / Employee

-$2,581,541

Market Cap

584.22M

Employees Chart

Employees History

Date	Employees	Change	Growth
Dec 31, 2024	220	169	331.37%
Dec 31, 2023	51	-2	-3.77%
Dec 31, 2022	53	-11	-17.19%
Dec 31, 2021	64	28	77.78%
Dec 31, 2020	36	-	-

Related Stocks

Company Name	Employees
UnitedHealth Group	400,000
Johnson & Johnson	138,100
Thermo Fisher Scientific	125,000
Abbott Laboratories	114,000
AstraZeneca	92,900
Novo Nordisk	77,349
Novartis AG	75,883
Merck & Co.	75,000

Employee Rankings

NUVB News

5 days ago - Nuvation Bio to Present New Nonclinical Data for Taletrectinib at the American Association for Cancer Research Annual Meeting 2025 - Business Wire
6 days ago - Nuvation Bio to Present Matching-adjusted Indirect Comparison Data for Taletrectinib vs. Crizotinib During Mini Oral Presentation at the European Lung Cancer Congress 2025 - Business Wire
24 days ago - Nuvation Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update - Business Wire
4 weeks ago - Nuvation Bio Secures Up to $250 Million in Non-Dilutive Financings from Sagard Healthcare Partners - Business Wire
5 weeks ago - Nuvation Bio to Present at the TD Cowen 45th Annual Health Care Conference - Business Wire
5 weeks ago - Kuehn Law Encourages Investors of Nuvation Bio Inc. to Contact Law Firm - PRNewsWire
6 weeks ago - Nuvation Bio: Pending Approval Shot In ROSL+ NSCLS Looks A Major Upside Catalyst - Seeking Alpha
2 months ago - Nuvation Bio Announces Expanded Access Program in the U.S. for Taletrectinib in Advanced ROS1-positive Non-Small Cell Lung Cancer - Business Wire